MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00543595
Recruitment Status : Completed
First Posted : October 15, 2007
Last Update Posted : May 22, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:

This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Metabolic Syndrome Drug: MK0916 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 154 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : August 2004
Actual Primary Completion Date : May 2005
Actual Study Completion Date : May 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have Type 2 Diabetes
  • 18 to 65 years of age

Exclusion Criteria:

  • History of Type 1 Diabetes Mellitus
  • Have been treated with insulin in the past 8 weeks
  • On a weight loss program and have ongoing weight loss
  • Taking weight loss medication
  • Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery
  • Have taken another investigational drug in the last 8 weeks
  • Have active liver disease
  • Have a history of major surgery involving gastric or intestinal bypass

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00543595

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.

Publications of Results:
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00543595     History of Changes
Other Study ID Numbers: 0916-005
First Posted: October 15, 2007    Key Record Dates
Last Update Posted: May 22, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Metabolic Syndrome X
Diabetes Mellitus, Type 2
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Resistance